Skip to main content

Table 3 Therapeutic interventions for AE-IPF

From: Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial

 

rhTM group (n = 10)

Untreated group (n = 13)

m-PSL pulse therapy

10/10

13/13

rhTM therapy

10/10

0/13

Empiric antibiotic therapy

4/10

13/13

Sivelestat sodium hydrate

0/10

6/13

Immunosuppressant (cyclosporine, cyclophosphamide)

0/10

6/13

Polymyxin B-immobilized fiber column treatment

0/10

3/13

Noninvasive positive pressure ventilation

1/10

0/13

Invasive mechanical ventilation

1/10

4/13

  1. AE-IPF acute exacerbation of idiopathic pulmonary fibrosis, rhTM recombinant human soluble thrombomodulin, m-PSL pulse therapy intravenous methylprednisolone 1 g/day for 3 days, rhTM therapy intravenous recombinant human soluble thrombomodulin of 380 U/kg/day for 7 days